Global
News Centre
Company News Media Coverage

Year

2024
2023
2022
2021
2020
2019
2018

Month

01
02
03
04
05
06
07
08
09
10
11
12
2022-07-25 16:12
An exclusive interview with Pr...
Introduction: The incidence of microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) in patients with solid tumors is approximately 10%-22% [1], with a higher incidence for c...
More
2021-08-05 09:08
The First Domestic TF ADC Drug
On August 5, 2021, a clinical trial application of MRG004A, a new TF-targeted ADC drug manufactured by LEPU BIOPHARMA, was impliedly approved by the NMPA.   Acceptance No. ...
More
2021-07-22 10:01
MRG003 Hopefully Reshape the T
Lung cancer is characterized by the highest incidence rate and mortality rate among malignant tumors in China, and non-small cell lung cancer (NSCLC) is the most common type of the lung cancer, a...
More
2021-07-19 17:42
LEPU BIOPHARMA Conducting a Cl...
Nowadays, breast cancer has replaced the lung cancer to become the leading cancer in the world which seriously threatens women's health. The anti-HER2 therapy is the cornerston...
More
<12
Home Page
Company Profile
Strategic Investors
Technical Strength
News Centre
About Us
Company Profile
Milestones
Core Team
Science and Technology
Research Field
Technology Platform
Product Pipeline
Manufacturing Plants
Intellectual Property Rights
Investor Relations
Company Information
Financial Reports
Announcements and Circulars
Corporate Governance
News Centre
Company News
Media Coverage
Join Us
Corporate Culture
Business Outlook
Benefits
Job Opportunities
Contact us
Copyright 2021 By Lepu Biopharma CO.,Ltd.
京公网安备11011702000459号京ICP备20018649号-1

Home Page
About Us
Science and Technology
Strategic Investors
News Centre
Join Us
Contact Us